ArticleJournal of thrombosis and thrombolysis2026
Multi target effects of Allium macrostemon against myocardial infarction: an integrated network pharmacology, molecular docking, and experimental study.
Article in Journal of thrombosis and thrombolysis, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
backgroundMyocardial infarction (MI), a leading cause of global mortality, is inadequately managed by current therapies due to incomplete efficacy and adverse effects. This study aimed to investigate the multi-target mechanisms of Allium macrostemon Bunge (AM) against MI using an integrative strategy.
methodsBioactive compounds and MI‑related targets of AM were predicted via network pharmacology and validated by molecular docking. The chemical profile of the AM water decoction was characterized by liquid chromatography‑tandem mass spectrometry (LC‑MS/MS). A rat MI model was established to evaluate the cardioprotective effects of AM, including infarct size, platelet aggregation, and coagulation parameters (prothrombin time [PT] and activated partial thromboplastin time [APTT]).
resultsNetwork pharmacology identified 11 bioactive compounds and 63 MI-related targets. Molecular docking confirmed strong binding between flavonoids and critical targets. LC‑MS/MS analysis of the AM decoction revealed a complex chemical profile, including the detection of N‑trans‑feruloyltyramine, a known antiplatelet compound, as a key overlapping constituent. AM reduced infarct size, suppressed platelet activation and cardiac injury markers, restored cardiomyocyte integrity, inhibited fibrosis and macrophage infiltration, with high-dose AM comparable to aspirin. Moreover, AM did not prolong PT or APTT, indicating a favorable bleeding risk profile.
conclusionAM alleviates MI through multi‑target regulation of apoptosis and inflammation, and shows antiplatelet efficacy comparable to aspirin under the present experimental conditions, without prolonging PT or APTT.
Indexed as
Identifiers
42397505What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.